News

Hosted on MSN23d
Retatrutide (LY3437943): A Comprehensive Review of Its Therapeutic Potential in Obesity and Type 2 Diabetes Mellitus
(2025) demonstrated superior efficacy of retatrutide compared to Liraglutide and Tirzepatide in a diabetic kidney disease model using db/db mice.2 Over a 10-week intervention, retatrutide ...
Retatrutide (LY3437943): A Novel Tri-agonist Peptide for Metabolic Disease Treatment
TUCSON, AZ / ACCESS Newswire / April 29, 2025 / Retatrutide, also known as LY3437943, is an innovative triple receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), ...